| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
|
N Engl J Med
|
2011
|
28.99
|
|
2
|
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
|
Eur Heart J
|
2012
|
18.18
|
|
3
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
|
N Engl J Med
|
2009
|
18.03
|
|
4
|
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
|
N Engl J Med
|
2012
|
8.88
|
|
5
|
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
|
N Engl J Med
|
2013
|
4.16
|
|
6
|
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
|
Circulation
|
2012
|
4.10
|
|
7
|
Intravenous platelet blockade with cangrelor during PCI.
|
N Engl J Med
|
2009
|
3.31
|
|
8
|
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
|
N Engl J Med
|
2011
|
3.20
|
|
9
|
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study.
|
Eur Heart J
|
2006
|
3.14
|
|
10
|
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.
|
N Engl J Med
|
2002
|
3.01
|
|
11
|
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
|
JAMA
|
2004
|
2.89
|
|
12
|
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
|
Lancet Neurol
|
2012
|
2.77
|
|
13
|
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
|
J Am Coll Cardiol
|
2008
|
2.67
|
|
14
|
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
|
JAMA
|
2008
|
2.59
|
|
15
|
Platelet inhibition with cangrelor in patients undergoing PCI.
|
N Engl J Med
|
2009
|
2.52
|
|
16
|
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
|
Circulation
|
2008
|
2.40
|
|
17
|
Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting.
|
Am J Cardiol
|
2006
|
2.40
|
|
18
|
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
|
Eur Heart J
|
2011
|
2.31
|
|
19
|
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
|
Circulation
|
2008
|
2.19
|
|
20
|
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
|
J Am Coll Cardiol
|
2013
|
2.17
|
|
21
|
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
|
Lancet
|
2009
|
2.13
|
|
22
|
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
|
Am Heart J
|
2013
|
2.12
|
|
23
|
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
|
Circulation
|
2003
|
2.09
|
|
24
|
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
|
Circulation
|
2013
|
2.03
|
|
25
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
|
J Am Coll Cardiol
|
2010
|
2.00
|
|
26
|
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Eur Heart J
|
2011
|
1.98
|
|
27
|
Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
|
J Clin Oncol
|
2010
|
1.98
|
|
28
|
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.
|
Am J Cardiol
|
2005
|
1.96
|
|
29
|
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial.
|
Eur Heart J
|
2007
|
1.95
|
|
30
|
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
|
Circulation
|
2012
|
1.84
|
|
31
|
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2013
|
1.77
|
|
32
|
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF.
|
Am Heart J
|
2011
|
1.72
|
|
33
|
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
|
Postgrad Med
|
2010
|
1.70
|
|
34
|
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
|
Circulation
|
2007
|
1.67
|
|
35
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
|
Circulation
|
2012
|
1.66
|
|
36
|
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
|
Circulation
|
2013
|
1.63
|
|
37
|
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
|
Eur Heart J
|
2013
|
1.56
|
|
38
|
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
|
Circulation
|
2014
|
1.54
|
|
39
|
The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction.
|
Crit Care Med
|
2013
|
1.52
|
|
40
|
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.
|
Int J Cardiol
|
2009
|
1.45
|
|
41
|
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial.
|
Heart
|
2013
|
1.45
|
|
42
|
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
|
JAMA
|
2004
|
1.44
|
|
43
|
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).
|
J Am Coll Cardiol
|
2014
|
1.43
|
|
44
|
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).
|
J Nucl Cardiol
|
2015
|
1.41
|
|
45
|
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.
|
J Am Coll Cardiol
|
2006
|
1.37
|
|
46
|
Sharing Data from Cardiovascular Clinical Trials - A Proposal.
|
N Engl J Med
|
2016
|
1.34
|
|
47
|
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
|
Clin J Am Soc Nephrol
|
2007
|
1.34
|
|
48
|
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
|
J Am Coll Cardiol
|
2010
|
1.31
|
|
49
|
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI).
|
Am J Cardiol
|
2010
|
1.27
|
|
50
|
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
|
J Am Heart Assoc
|
2013
|
1.26
|
|
51
|
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.
|
Am J Gastroenterol
|
2010
|
1.24
|
|
52
|
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
|
J Am Coll Cardiol
|
2013
|
1.23
|
|
53
|
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.
|
Am J Gastroenterol
|
2008
|
1.21
|
|
54
|
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
|
J Am Heart Assoc
|
2013
|
1.15
|
|
55
|
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years.
|
Int J Cardiol
|
2012
|
1.12
|
|
56
|
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
|
Circulation
|
2010
|
1.12
|
|
57
|
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.
|
Int J Cardiol
|
2013
|
1.11
|
|
58
|
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
|
J Am Coll Cardiol
|
2003
|
1.11
|
|
59
|
Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction.
|
Curr Control Trials Cardiovasc Med
|
2005
|
1.10
|
|
60
|
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
|
Am Heart J
|
2012
|
1.05
|
|
61
|
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.
|
Am Heart J
|
2012
|
1.04
|
|
62
|
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.
|
JACC Cardiovasc Interv
|
2008
|
1.02
|
|
63
|
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
|
Nephrol Dial Transplant
|
2012
|
1.01
|
|
64
|
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
|
J Clin Endocrinol Metab
|
2013
|
0.98
|
|
65
|
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.97
|
|
66
|
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).
|
Circulation
|
2014
|
0.96
|
|
67
|
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.96
|
|
68
|
Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
0.95
|
|
69
|
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
|
Stroke
|
2014
|
0.94
|
|
70
|
Publication or presentation of results from multicenter clinical trials: evidence from an academic medical center.
|
Am Heart J
|
2007
|
0.94
|
|
71
|
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
|
Circ Heart Fail
|
2013
|
0.93
|
|
72
|
Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee.
|
Contemp Clin Trials
|
2006
|
0.92
|
|
73
|
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.
|
J Thromb Thrombolysis
|
2012
|
0.90
|
|
74
|
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
|
J Am Coll Cardiol
|
2006
|
0.90
|
|
75
|
Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
|
J Am Coll Cardiol
|
2009
|
0.90
|
|
76
|
Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis.
|
Cardiology
|
2002
|
0.89
|
|
77
|
Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.
|
Biostatistics
|
2010
|
0.89
|
|
78
|
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
|
Catheter Cardiovasc Interv
|
2007
|
0.89
|
|
79
|
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
|
Am Heart J
|
2006
|
0.89
|
|
80
|
Statin use and sex-specific stroke outcomes in patients with vascular disease.
|
Stroke
|
2006
|
0.88
|
|
81
|
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial).
|
Am J Cardiol
|
2006
|
0.87
|
|
82
|
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
|
Eur Heart J
|
2007
|
0.87
|
|
83
|
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
|
Am Heart J
|
2013
|
0.86
|
|
84
|
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
|
Eur Heart J
|
2005
|
0.86
|
|
85
|
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction.
|
Eur Heart J
|
2006
|
0.86
|
|
86
|
Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation.
|
Am J Med
|
2013
|
0.86
|
|
87
|
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
|
Curr Opin Cardiol
|
2010
|
0.86
|
|
88
|
Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction.
|
Coron Artery Dis
|
2012
|
0.86
|
|
89
|
Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.86
|
|
90
|
Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury.
|
Am J Physiol Heart Circ Physiol
|
2013
|
0.86
|
|
91
|
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
|
Am Heart J
|
2002
|
0.86
|
|
92
|
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
|
J Am Heart Assoc
|
2014
|
0.85
|
|
93
|
Rivaroxaban, an oral direct factor Xa inhibitor.
|
Expert Opin Investig Drugs
|
2008
|
0.85
|
|
94
|
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.
|
JACC Cardiovasc Interv
|
2013
|
0.85
|
|
95
|
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction.
|
Am Heart J
|
2006
|
0.85
|
|
96
|
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
|
J Am Coll Cardiol
|
2012
|
0.85
|
|
97
|
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends.
|
J Am Coll Cardiol
|
2013
|
0.84
|
|
98
|
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
|
J Am Coll Cardiol
|
2012
|
0.84
|
|
99
|
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry.
|
Eur Heart J
|
2005
|
0.84
|
|
100
|
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.
|
Am Heart J
|
2013
|
0.84
|
|
101
|
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
|
Eur Heart J
|
2008
|
0.83
|
|
102
|
Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease.
|
J Thorac Cardiovasc Surg
|
2009
|
0.82
|
|
103
|
Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade.
|
Catheter Cardiovasc Interv
|
2005
|
0.82
|
|
104
|
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
|
Circ Cardiovasc Qual Outcomes
|
2011
|
0.82
|
|
105
|
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.
|
Am Heart J
|
2013
|
0.81
|
|
106
|
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes.
|
Am J Med
|
2010
|
0.81
|
|
107
|
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
|
Catheter Cardiovasc Interv
|
2010
|
0.81
|
|
108
|
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
|
Am Heart J
|
2012
|
0.81
|
|
109
|
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome.
|
Am Heart J
|
2008
|
0.81
|
|
110
|
Promises of PAR-1 inhibition in acute coronary syndrome.
|
Curr Cardiol Rep
|
2012
|
0.81
|
|
111
|
Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict.
|
Am Heart J
|
2008
|
0.80
|
|
112
|
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV).
|
Am J Cardiol
|
2008
|
0.80
|
|
113
|
N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction.
|
Can J Cardiol
|
2006
|
0.80
|
|
114
|
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY.
|
Am Heart J
|
2010
|
0.80
|
|
115
|
Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.
|
Drugs
|
2005
|
0.80
|
|
116
|
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
|
Thromb Haemost
|
2014
|
0.80
|
|
117
|
Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches.
|
Am Heart J
|
2013
|
0.80
|
|
118
|
Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial.
|
Am Heart J
|
2005
|
0.80
|
|
119
|
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
|
Eur Heart J
|
2013
|
0.79
|
|
120
|
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
|
J Thromb Thrombolysis
|
2011
|
0.79
|
|
121
|
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy.
|
Trials
|
2013
|
0.79
|
|
122
|
Baseline glucose and left ventricular remodeling after acute myocardial infarction.
|
J Diabetes Complications
|
2007
|
0.79
|
|
123
|
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
|
J Thromb Thrombolysis
|
2015
|
0.79
|
|
124
|
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
|
Am Heart J
|
2006
|
0.79
|
|
125
|
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
|
Am J Cardiol
|
2004
|
0.79
|
|
126
|
Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction.
|
Coron Artery Dis
|
2012
|
0.78
|
|
127
|
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
|
Am Heart J
|
2004
|
0.78
|
|
128
|
Management of acute coronary syndromes in patients with renal dysfunction.
|
Curr Opin Cardiol
|
2008
|
0.78
|
|
129
|
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.
|
J Thromb Thrombolysis
|
2011
|
0.77
|
|
130
|
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
|
Circulation
|
2013
|
0.77
|
|
131
|
The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes.
|
Curr Cardiol Rep
|
2004
|
0.77
|
|
132
|
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction.
|
Eur Heart J
|
2009
|
0.77
|
|
133
|
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial.
|
J Am Coll Cardiol
|
2016
|
0.77
|
|
134
|
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction".
|
Am Heart J
|
2011
|
0.76
|
|
135
|
Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial).
|
Am J Cardiol
|
2005
|
0.76
|
|
136
|
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes.
|
Am J Med
|
2004
|
0.76
|
|
137
|
Determinants of plasma vitamin D levels in patients with acute coronary syndromes.
|
Eur J Clin Invest
|
2011
|
0.76
|
|
138
|
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
|
Am Heart J
|
2013
|
0.76
|
|
139
|
Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels.
|
Thromb Res
|
2003
|
0.76
|
|
140
|
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
|
J Thromb Thrombolysis
|
2006
|
0.76
|
|
141
|
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
|
Am Heart J
|
2005
|
0.76
|
|
142
|
Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions.
|
JAMA
|
2007
|
0.75
|
|
143
|
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
|
Circulation
|
2014
|
0.75
|
|
144
|
Venous thromboembolism: yet another cardiovascular complication of chronic kidney disease?
|
Circulation
|
2012
|
0.75
|
|
145
|
The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy.
|
Circulation
|
2006
|
0.75
|
|
146
|
Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?
|
Eur Heart J
|
2013
|
0.75
|
|
147
|
Clopidogrel and PPI interaction: clinically relevant or not?
|
Curr Cardiol Rep
|
2012
|
0.75
|
|
148
|
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
|
Am J Cardiol
|
2009
|
0.75
|
|
149
|
Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies.
|
Am Heart J
|
2003
|
0.75
|
|
150
|
Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.
|
J Thromb Thrombolysis
|
2013
|
0.75
|
|
151
|
"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
152
|
Influence of clinical trial participation on subsequent antithrombin use.
|
Clin Cardiol
|
2010
|
0.75
|
|
153
|
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
154
|
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
|
J Thromb Thrombolysis
|
2012
|
0.75
|
|
155
|
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
|
Am Heart J
|
2007
|
0.75
|
|
156
|
Lost to Follow-up and Withdrawal of Consent in Contemporary Global Cardiovascular Randomized Clinical Trials.
|
Crit Pathw Cardiol
|
2015
|
0.75
|
|
157
|
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes.
|
Am J Med
|
2003
|
0.75
|
|
158
|
Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
|
Pharm Stat
|
2015
|
0.75
|
|
159
|
Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes.
|
J Interv Cardiol
|
2002
|
0.75
|
|
160
|
Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes.
|
Expert Opin Pharmacother
|
2005
|
0.75
|
|
161
|
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
|
Coron Artery Dis
|
2013
|
0.75
|
|
162
|
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
|
Thromb Haemost
|
2017
|
0.75
|
|
163
|
Promise of factor Xa inhibition in atrial fibrillation.
|
Curr Cardiol Rep
|
2012
|
0.75
|
|
164
|
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes.
|
J Am Coll Cardiol
|
2013
|
0.75
|
|
165
|
Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes.
|
Eur Heart J
|
2009
|
0.75
|
|
166
|
Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
|
Coron Artery Dis
|
2016
|
0.75
|
|
167
|
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
|
Am Heart J
|
2004
|
0.75
|
|
168
|
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials.
|
EuroIntervention
|
2017
|
0.75
|